Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo aims to turn Chemo-Resistant breast cancer curable

NCT ID NCT07457359

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new approach for people with triple-negative breast cancer whose tumors don't shrink after standard chemotherapy. Participants receive targeted radiation to the tumor followed by immunotherapy (toripalimab) plus more chemo. The goal is to see if this combination can eliminate all cancer before surgery, allowing more patients to have breast-conserving surgery instead of mastectomy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TNBC, TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Department of Radiation Oncology，the Second Affiliated Hospital of Zhejiang University School of Medicine, hangzhou, zhejiang

    RECRUITING

    Hangzhou, China